Monte Rosa Therapeutics, Inc. (GLUE) Fair Value 2026

GLUE · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.3 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-15, Monte Rosa Therapeutics, Inc. (GLUE) trades at $23.41, approximately 301% above CirclFi’s Bayesian DCF fair value of $5.84. QOC: 5.3/10. Value Trap Risk: 24/100 (SAFE). 12/13 models active.

Key Facts

Ticker
GLUE
Price
$23.41
Quality Score
5.3/10
Value Trap Risk
24/100
Models Active
12/13
Last Updated
Strength: 12 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Monte Rosa Therapeutics, Inc. (GLUE) Undervalued or Overvalued in 2026?

According to CirclFi’s 12-model valuation engine, Monte Rosa Therapeutics, Inc. (GLUE) appears overvalued as of : the median of 12 independent fair value estimates is $5.11, 78.2% below the current price of $23.41. Estimates range from $0.46 to $17.90. GLUE scores 5.3/10 on fundamental quality and 24/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Monte Rosa Therapeutics, Inc. Stock in 2026? →

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($23.41)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
 $5.84 -75.0%
Earnings Power Value
Medium Conviction
 $3.72 -84.1%
CUCE Ensemble
Low Conviction
 $7.03 -70.0%
First Chicago
Medium Conviction
 $2.85 -87.8%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Monte Rosa Therapeutics, Inc. (GLUE) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Monte Rosa Therapeutics, Inc.'s intrinsic value is estimated at $6.72, suggesting the stock is overvalued at its current price of $23.41. With 12 out of 12 models flagging downside (-71.3% average return), the market may be pricing in unsustainable growth. Notably, FTNN sees the most upside at -23.5% (fair value: $17.90), while ML-RIV is the most conservative at -98.1% ($0.46). The spread between these extremes — +74.5% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About GLUE?

12 of 13 models are currently active for GLUE. All 12 active models suggest the stock trades above fair value. The Bayesian DCF estimates GLUE's intrinsic value at $5.84, implying -75.0% downside from the current price. See which stocks rank higher →

How Does GLUE Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, GLUE ranks #65 by Quality of Company score. CirclFi's QOC score of 5.3/10 evaluates 32 fundamental signals. A score of 5.3 reflects mixed fundamentals.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

Monte Rosa Therapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is GLUE a Value Trap?

CirclFi's Value Trap algorithm assigns GLUE a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Monte Rosa Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Monte Rosa Therapeutics, Inc. is rated at 5.3/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

The gap between the most bullish and bearish model spans +74.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every GLUE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across GLUE's 12 active models, average confidence is 33%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Monte Rosa Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About Monte Rosa Therapeutics, Inc.

What is Monte Rosa Therapeutics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Monte Rosa Therapeutics, Inc. (GLUE) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $5.84. The Quality of Company score is 5.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is GLUE overvalued or undervalued right now?

At $23.41, 0 of 12 active models suggest GLUE may be undervalued, while 12 indicate potential overvaluation. The median of all 12 fair value estimates is $5.11, 78.2% below the current price of $23.41 — a consensus view that GLUE is overvalued. The assessment depends on which methodology best fits Monte Rosa Therapeutics, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 5.3 mean for GLUE?

Monte Rosa Therapeutics, Inc.'s QOC of 5.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on GLUE?

CirclFi analyzes GLUE with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is GLUE a value trap in 2026?

Monte Rosa Therapeutics, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 12-model valuation engine, Monte Rosa Therapeutics, Inc. (GLUE) has a median fair value of $5.11 — 78.2% below the current price of $23.41 — as of 2026-07-15.” Source: circlfi.com/stock/GLUE/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on GLUE.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access